← Back to Search

Fluorothymidine (FLT) for Graft-versus-Host Disease

Phase < 1
Waitlist Available
Led By Z Lee, MD/PhD
Research Sponsored by UNC Lineberger Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Allogeneic transplant patients receiving either a fully myeloablative or reduced intensity chemotherapy +/- total body irradiation (TBI) conditioning regimen are eligible.
Patients undergoing autologous bone marrow transplant for multiple myeloma
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 100 days (approximate)
Awards & highlights

Study Summary

This trial is testing a new way to give the stem cells that may help prevent GVHD while still allowing the new cells to attack the cancer cells.

Eligible Conditions
  • Graft-versus-Host Disease

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~100 days (approximate)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 100 days (approximate) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall FLT-PET Bone Marrow Signal
Overall FLT-PET Signal Intensity within Host Secondary Lymphoid Sites
Secondary outcome measures
Differences in FLT Uptake in Autologous HSCT and Allogeneic HSCT Patients
Isolated/Asymmetric Foci of Increased FLT
Overall FLT-PET Signal Intensity and Acute Graft Versus Host Disease
+7 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: AutologousExperimental Treatment1 Intervention
3 patients undergoing autologous stem cell transplant will also undergo Fluorothymidine FLT-PET-MRI imaging the same two time points in order to determine how much of the FLT signal observed after allogeneic transplant is unique to that population and the result of allo-antigen driven T cell expansion.
Group II: AllogeneicExperimental Treatment1 Intervention
A total of 12 patients who have undergone allogenic bone marrow transplantation will undergo Fluorothymidine FLT-PET-MRI imaging on two separate occasions.

Find a Location

Who is running the clinical trial?

UNC Lineberger Comprehensive Cancer CenterLead Sponsor
348 Previous Clinical Trials
88,234 Total Patients Enrolled
Z Lee, MD/PhDPrincipal InvestigatorUniversity of North Carolina, Chapel Hill

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any existing openings for participants in this research study?

"Clinicaltrials.gov states that this particular medical trial is not presently enrolling patients, despite its first posting dating back to January 1st 2017 and last update on March 21st 2022. However, 181 alternative studies are currently taking part in recruitment efforts."

Answered by AI

Are individuals aged 40 and above eligible for inclusion in this research?

"As indicated by the eligibility requirements, individuals aged 18 to 99 can apply for this trial. If an applicant is younger than 18 or older than 65, they may be eligible for one of 67 trials targeting minors or 156 studies recruiting senior citizens respectively."

Answered by AI

Is this the first instance of research like this?

"Fluorothymidine (FLT) has been the subject of research since 2014, when GenVivo Inc. sponsored its first study involving 122 participants. After receiving Phase 1 drug approval in 2014, numerous active trials have been launched across 12 cities and 5 countries to further explore FLT's efficacy."

Answered by AI

What other experiments have used Fluorothymidine (FLT) to measure outcomes?

"Currently, 12 clinical studies are in progress to research Fluorothymidine (FLT). Of those trials, none have reached the third stage of testing. Buffalo, New york is home to several such tests while 29 other medical sites around the United States also host these investigations."

Answered by AI

What results are researchers expecting to observe from the trial?

"Over the 35 day duration of this trial, researchers aim to gauge Overall FLT-PET Signal Intensity within Host Secondary Lymphoid Sites. Additionally, they will be monitoring Strength of the FLT-PET Signal and Bone Marrow Cellularity in allogeneic stem cell transplant recipients as well as any Differences in FLT Uptake between Autologous HSCT and Allogeneic HSCT Patients, plus isolated/asymmetric Foci of Increased FLT relative to disease relapse incidence by Day +100 for allogeneic stem cell transplant patients."

Answered by AI

Is my candidacy suitable for inclusion in this research?

"This clinical trial seeks to enlist 15 individuals with graft vs host disease, ranging from 18 to 99 years old. To qualify for the study, candidates must meet specific criteria such as undergoing autologous bone marrow transplant for multiple myeloma and being in a complete morphologic remission prior to allogeneic transplantation when receiving either chemotherapy or total body irradiation conditioning regimen alongside stem cells from matched related/unrelated or mismatched related (including haplotype-matched) donors."

Answered by AI

How many individuals have been recruited for this experiment?

"This clinical trial is no longer enrolling patients, as the last edit was made on March 21st 2022. If you are seeking alternative trials, there are currently 169 studies for graft vs host disease and 12 for Fluorothymidine (FLT) actively admitting participants."

Answered by AI
~1 spots leftby Mar 2025